Research programme: in vivo gene therapies - Elevatebio
Latest Information Update: 20 May 2024
At a glance
- Originator ElevateBio
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 15 May 2024 ElevateBio has patent protection for multiple enzymes including RNA-guided nucleases, adenine deaminases, base editors and reverse transcriptase editors in the US
- 24 May 2023 RP created from - https://elevate.bio/therapeutic-design-approaches/in-vivo-gene-therapies/; 9389759, after discussion with SME
- 16 May 2023 Early research in Unspecified in USA (Parenteral) (Elevatebio website)